Literature DB >> 30017020

Refinement and Successful Implementation of a Scoring System for Myxomatosis in a Susceptible Rabbit (Oryctolagus cuniculus) Model.

A Marissa Wolfe1, Masmudur Rahman2, D Grant McFadden2, Eric C Bartee3.   

Abstract

Myxoma virus is a member of Leporipoxviridae whose tropism is tightly restricted to lagomorphs. In susceptible Oryctolagus rabbits, the virus causes a highly lethal disease known as myxomatosis, which begins as a localized infection but rapidly disseminates throughout the animal, leading to immune compromise, mucosal infections, multiorgan failure, and death. In a research setting, myxoma infection of susceptible Oryctolagus cuniculus rabbits is used as a model of poxviral disease progression and represents one of only a few means to study the pathogenesis of this viral family in a native host species. However, the rapid progression of myxomatosis makes accurate prediction of humane endpoints critical to limiting animal pain and distress and preventing death as an endpoint. Here we present case studies of myxomatosis at 2 institutions and offer a refined scoring system to reliably track the course of disease in susceptible rabbits infected with myxoma virus.

Entities:  

Mesh:

Year:  2018        PMID: 30017020      PMCID: PMC6103426          DOI: 10.30802/AALAS-CM-18-000024

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  12 in total

1.  The complete DNA sequence of myxoma virus.

Authors:  C Cameron; S Hota-Mitchell; L Chen; J Barrett; J X Cao; C Macaulay; D Willer; D Evans; G McFadden
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

Review 2.  Recognizing pain and distress in laboratory animals.

Authors:  E Carstens; G P Moberg
Journal:  ILAR J       Date:  2000

Review 3.  Defining the moribund condition as an experimental endpoint for animal research.

Authors:  L A Toth
Journal:  ILAR J       Date:  2000

Review 4.  Humane endpoints for infectious disease animal models.

Authors:  E D Olfert; D L Godson
Journal:  ILAR J       Date:  2000

5.  Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer.

Authors:  John C Bell; Grant McFadden
Journal:  Curr Opin Virol       Date:  2015-08-07       Impact factor: 7.090

Review 6.  VSV-tumor selective replication and protein translation.

Authors:  Glen N Barber
Journal:  Oncogene       Date:  2005-11-21       Impact factor: 9.867

Review 7.  What the literature tells us about score sheet design.

Authors:  Philippe Bugnon; Maike Heimann; Michaela Thallmair
Journal:  Lab Anim       Date:  2016-12       Impact factor: 2.471

8.  Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulence.

Authors:  Stephanie A Lamb; Masmudur M Rahman; Grant McFadden
Journal:  Virology       Date:  2014-07-26       Impact factor: 3.616

9.  Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.

Authors:  Nancy Y Villa; Swarna Bais; Winnie M Chan; Amy M Meacham; Elizabeth Wise; Masmudur M Rahman; Jan S Moreb; Emma H Rosenau; John R Wingard; Grant McFadden; Christopher R Cogle
Journal:  Cytotherapy       Date:  2016-03       Impact factor: 5.414

10.  Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.

Authors:  Veronica G Kinn; Valerie A Hilgenberg; Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2016-08-08
View more
  1 in total

1.  Myxomatosis and Rabbit Haemorrhagic Disease: A 30-Year Study of the Occurrence on Commercial Farms in Spain.

Authors:  Joan M Rosell; L Fernando de la Fuente; Francisco Parra; Kevin P Dalton; J Ignacio Badiola Sáiz; Ana Pérez de Rozas; Juan J Badiola Díez; Daniel Fernández de Luco; Jordi Casal; Natàlia Majó; Jordina Casas; Ricard Garriga; Xosé M Fernández Magariños
Journal:  Animals (Basel)       Date:  2019-10-10       Impact factor: 2.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.